Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 13/20 | 0.49 |
| ▸ | PDE4A | P27815 | 9/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.49 |
| ▸ | CCR5 | P51681 | 3/20 | 0.42 |
| ▸ | QPCT | Q16769 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2909446 | 0.91 | PDE4D (0.45) | PDE4DPDE4APDE4BPDE4CCCR5 | |
| SCHEMBL1157563 | 0.82 | PDE4D (0.54) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1157823 | 0.81 | PDE4D (0.53) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1157852 | 0.79 | PDE4D (0.49) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1157485 | 0.79 | PDE4D (0.48) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1157546 | 0.79 | PDE4D (0.47) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1157887 | 0.78 | PDE4D (0.48) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1157321 | 0.78 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1157807 | 0.78 | PDE4D (0.49) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2908928 | 0.77 | GPR119 (0.42) | PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | MEMORY PHARMACEUTICAL CORPORATION | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | PDE4A, PDE4B, PDE3B | PDE4D 6/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.